Appriss Health provides the nation’s most comprehensive platform for early identification, prevention and management of substance use disorders.
Appriss Health focuses on analytics and data-driven solutions to help address patient safety and substance misuse potential through both controlled substance data and analytics solutions and the monitoring of over-the-counter methamphetamine precursors.
Appriss Health’s PDMP platform, PMP AWARxE, is now live in 30 states and provides access to mandatory pharmacy reporting with secure accessibility to data across state lines. Integration technology, with Appriss Health’s PMP Gateway, integrates state PDMP data into physician and pharmacist workflows to provide real-time data at the point-of-care.
NarxCare (the next evolution of NarxCheck) adds an advanced layer of analytics and risk scoring to enable better prescribing and dispensing decisions.
With solutions for both prescription monitoring and methamphetamine precursor tracking, Appriss Health is instrumental in providing data and analytic solutions to inform and support decision-making related to substance use disorders.
View multi-state PDMP data, right from your EHR workflow, along with prescribing risk scores and care management tools.
Block illegal purchases of methamphetamine precursors right at the point of sale, without preventing access to the customers who need these medicines most.
PMP Interconnect (PMPi), in conjunction with Appriss Health and the National Association of Boards of pharmacy is the national PMP data exchange hub that enables the secure sharing of PMP data across states and systems.
44 states are actively engaged with interstate data sharing via PMP Interconnect.
Over 6 million patient reports are being routed via PMP Interconnect.
PMP Interconnect is available at NO COST to states.